Medical Technology

Medical Device Industry Commends the Government’s Recent Initiatives for the sector

AdvaMed

Members of AdvaMed, the Advanced Medical Technology AdvaMedAssociation, said that they are encouraged by the new government’s commitment to creating a regulatory framework that would help the industry better address the needs of Indian patients. Addressing a round table, Sanjay Banerjee, Chairman of the India Working Group of AdvaMed said, “We greatly appreciate the government’s decision to revise the Drugs & Cosmetics (Amendment) Bill. An appropriate, globally harmonised regulatory environment would enable us to improve access, availability and affordability of medical devices for the Indian patient. The passage of the D&C Bill 2015 will be a significant first step towards recognising medical devices as a distinct and crucial segment of the healthcare sector.”

In India, medical devices currently constitute only 6 percent of total healthcare spending. Its ability to address the country’s growing disease (particularly non-communicable disease) burden has historically been limited by the fact that medical devices are treated as drugs. Only 14 of the 14000 types of medical devices that exist are recognised in India, and even these are regulated as pharmaceuticals.

“As India’s disease burden transitions from communicable to non-communicable diseases (NCDs), medical technology will have an increasingly important role to play in saving and improving the quality of life of patients. It is particularly heartening that the Prime Minister and his government have taken note of this significance through their recent call to manufacturers to ‘Make in India’ and the decision to allow 100 percent FDI under the automatic route. We believe that the Drugs & Cosmetics (Amendment) Bill 2015 is an essential precursor to achieving these objectives,” said Vibhav Garg, Vice-Chair of the India Working Group of AdvaMed, an association whose members provide 40% of the medical technology used across the world. According to a 2014 CII-BCG report, within an appropriate regulatory environment, the sector could grow to US$ 50 billion by 2025.

“Going forward, we hope to engage in consistent dialogue with the government to ensure that the distinction between drugs and medical devices is indeed taken to the last mile in every sphere from manufacture to pricing to providing access,” said Banerjee.AdvaMed,

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon1Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top